Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
Coeptis Therapeutics Holdings (NASDAQ:COEP), a next-gen technology and biopharmaceutical company, has announced the extinguishment of its convertible note with YA II PN, Ltd (Yorkville). The note, which was dated January 16, 2025, represented the company's outstanding debt obligations to Yorkville.
CEO David Mehalick emphasized that clearing this debt strengthens the company's capital structure. The company views this debt clearance as strategically important as it plans to expand into cryptocurrency operations.
Coeptis Therapeutics Holdings (NASDAQ:COEP), un'azienda biotecnologica e farmaceutica di nuova generazione, ha annunciato l'estinzione della sua nota convertibile con YA II PN, Ltd (Yorkville). La nota, datata 16 gennaio 2025, rappresentava l'obbligazione debitoria residua della società nei confronti di Yorkville.
Il CEO David Mehalick ha sottolineato che la cancellazione di questo debito rafforza la struttura patrimoniale dell'azienda. La società considera questa estinzione del debito strategicamente importante in vista dell'espansione nelle operazioni legate alle criptovalute.
Coeptis Therapeutics Holdings (NASDAQ:COEP), una empresa biotecnológica y biofarmacéutica de próxima generación, ha anunciado la cancelación de su nota convertible con YA II PN, Ltd (Yorkville). La nota, fechada el 16 de enero de 2025, representaba las obligaciones de deuda pendientes de la empresa con Yorkville.
El CEO David Mehalick destacó que la eliminación de esta deuda fortalece la estructura de capital de la compañía. La empresa considera esta cancelación de deuda como estratégicamente importante mientras planea expandirse en operaciones de criptomonedas.
Coeptis Therapeutics Holdings (NASDAQ:COEP)는 차세대 기술 및 바이오제약 회사로서 YA II PN, Ltd (Yorkville)와의 전환사채를 상환했다고 발표했습니다. 해당 사채는 2025년 1월 16일 날짜로 회사가 Yorkville에 진 빚을 나타냅니다.
CEO David Mehalick는 이 부채 상환이 회사의 자본 구조를 강화한다고 강조했습니다. 회사는 암호화폐 사업 확장을 계획함에 있어 이 부채 청산을 전략적으로 중요한 것으로 보고 있습니다.
Coeptis Therapeutics Holdings (NASDAQ:COEP), une entreprise biopharmaceutique et technologique de nouvelle génération, a annoncé l'extinction de sa note convertible avec YA II PN, Ltd (Yorkville). La note, datée du 16 janvier 2025, représentait les obligations de dette en cours de la société envers Yorkville.
Le PDG David Mehalick a souligné que le remboursement de cette dette renforce la structure financière de l'entreprise. La société considère ce remboursement comme stratégiquement important alors qu'elle prévoit de s'étendre aux opérations liées aux cryptomonnaies.
Coeptis Therapeutics Holdings (NASDAQ:COEP), ein Unternehmen der nächsten Generation im Bereich Technologie und Biopharma, hat die Tilgung seiner Wandelanleihe bei YA II PN, Ltd (Yorkville) bekannt gegeben. Die Anleihe vom 16. Januar 2025 stellte die ausstehenden Schulden des Unternehmens gegenüber Yorkville dar.
CEO David Mehalick betonte, dass die Tilgung dieser Schulden die Kapitalstruktur des Unternehmens stärkt. Das Unternehmen sieht diese Schuldenbereinigung als strategisch wichtig an, da es plant, in den Kryptowährungsgeschäft zu expandieren.
- Complete extinguishment of convertible note debt obligations with Yorkville
- Strengthened capital structure through debt elimination
- Improved financial flexibility for strategic expansion into cryptocurrency operations
- Potential shift from core biopharmaceutical business to cryptocurrency operations may increase business risk
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).
The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company’s outstanding debt obligations to Yorkville.
David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, “The extinguishment of these outstanding debt obligations strengthens the Company’s capital structure and positions us well to pursue our long-term goals.”
Management notes that a streamlined capital structure free from the weight of unnecessary outstanding obligations will help the Company navigate its proposed strategic addition of operations in the cryptocurrency space.
About Coeptis Therapeutics Holdings
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination or spin out. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom
Cautionary Note Regarding Forward-Looking Statements.
This press release and statements of our management made in connection therewith contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Source: Coeptis Therapeutics
FAQ
What debt did Coeptis Therapeutics (COEP) extinguish in July 2025?
How will the debt extinguishment affect Coeptis (COEP) operations?
What are Coeptis Therapeutics' (COEP) plans for strategic expansion?
Who is the CEO of Coeptis Therapeutics (COEP)?
